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62 Poster Session-IThese data demonstrate that a combination of intrinsic and extrinsic
approaches can be used to shape a population of CAR1 T cells that
exhibit redirected specificity for CD19. Since the SB system has
achieved regulatory approval and the aAPC are being manufactured
to clinical grade through PACT/NHLBI, investigators are now
able to infuse cytolytic CD81 and CD41 T cells expressing markers
of central memory and ability to sustain proliferation.
Expression of CAR on CD81and CD41 T cells propagated on
aAPC with IL-2 1/- IL-21
Culture conditions CD41CAR1 CD81CAR1IL-2 42% 1%
IL-2 1 IL-21 22% 76%165
THE INTERACTION BETWEEN LEUKEMIA AND BONE MARROW STROMA
PROTECTS THE TUMOR CELLS FROM CHEMOTHERAPY- AND RADIO-
THERAPY-INDUCED APOPTOSIS
Barriga, F.2, Riquelme, E.2, Macanas, P.1, Besa, P.1, Broekhuizen, R.1,
DiPersio, J.F.3, Kalergis, A.2, Nervi, B.1 1Pontificia Universidad Catolica
de Chile, Santiago, Chile; 2Pontificia Universidad Catolica de Chile, San-
tiago, Chile; 3Washington University School of Medicine, Saint Louis,
Chile
Introduction: The tumor microenvironment is increasingly be-
ing recognized as a critical factor in mediating cancer development
and drug resistance. Despite a high response rate to chemotherapy,
the vast majority of patients with AML are destined to relapse due
to residual disease in the bone marrow (BM). We have previously
reported that AMD3100 (CXCR4 inhibitor) produces a rapid and
transient leukemia cell mobilization from BM into peripheral
blood, sensitizing leukemia cells to chemotherapy (ASH 2006,
Nervi et al).
Objectives:To evaluate the effect of the interaction between APL
and BM stroma in the expansion, survival and chemo/radio sensitiza-
tion of leukemia cells.
Results:We used amouse leukemia cell line generated by knock-
ing in the human PML-RARa cDNA (APL). To evaluate the phys-
ical interaction between APL cells and the bone marrow stromal
cells (BMSC), 5104 APL cells were cultured for 24h without or
with a BMSC monolayer (M2-10B4), or fibroblast monolayer (L-
cell). We observed 0%, 80% and 15% respectively (p\0.001). To
investigate the chemo/radio-sensitivity of APL cells, the latter
were cultured without and with BMSCs for 24h followed by the
addition of various increasing concentrations of AraC for 24h or ra-
diotherapy (xRt). Flow cytometric analysis of GR11 cells using ap-
optotic indicators such as Bcl-2, Annexin V and caspase-3 revealed
a significant protection from cell death of the APL cells by the BM
stroma. Furthermore, the analysis of the proliferative state of these
APL cells with or without stroma by flow cytometry using BrDU,
CFSE and PI showed a decreased cellular proliferation of APL cells
in the presence of BM stroma (7% proliferates with stroma versus
70% without stroma). N 5 24 mice were injected with 106 APL
cells iv and after 14 days the mice had an average of 10% APL cells
in the peripheral blood. Eight mice received 300cGy xRt in day 16,
and 8 mice received the combination of 300cGy 1 AMD3100 (1h
before and 3h later xRt to interrupt APL/stroma interaction). As
a control group 8 mice were left untreated. The mean survival for
the untreated, xRt, and xRt1AMDwere 21, 26 and 29 days respec-
tively (p\0,02).
Conclusion: BMmicroenvironment recruits APL cells to G0 and
increases antiapoptotic signals that protects leukemia cells from
apoptosis mediated by cytotoxic agents. The interruption of this
interaction may improve outcomes in leukemia therapy.166
OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR PA-
TIENTS WITH ACUTE LEUKEMIA TRANSFORMED FROM MYELOFIBROSIS
Ciurea, S.O., de Lima, M., Giralt, S., Alousi, A., Kebriaei, P.,
Khouri, I.F., Anderlini, P., Andersson, B.S., Hosing, C.M.,
Champlin, R.E., Popat, U. University of Texas MD Anderson Cancer
Center, Houston, TXBackground and Rationale: Transformation of myelofibrosis
(MF) to acute leukemia (.20% blasts) portends a grave prognosis. Al-
logeneic stem cell transplantation (ASCT) is a curative approach for
patients with acute leukemia; however, the outcomes of ASCT in pa-
tients withMF transformed to acute leukemia are currently unknown.
Methods: Fifty-one consecutive patients with either primary
(PMF) or secondary (SMF) were transplanted at UTMDACC after
1994. Thirteen patients who developed AML (25%), 10 arising from
PMF and 3 with SMF, received an ASCT from a sibling or matched
unrelated donor. Median age was 59 years. Five patients (38%) had
prior splenectomy. JAK2V617F mutation analysis was performed in
7, and was present in 5 patients. Cytogenetics were intermediate in
10 and poor-risk in 3 patients. Seven patients (54%) were not in remis-
sion at the time of transplant. Eleven of 13 patients received induction
chemotherapy; 6 achieved remission, while 7 had persistent disease at
the time of transplant. One patient had a prior autologous transplant
and 2 patients had prior allogeneic transplant for myelofibrosis. The
donors were matched siblings (7 patients), matched unrelated (4 pa-
tients) and 1 antigen mismatched relatives (2 patients). The stem cell
source was peripheral blood in 9 and bone marrow in 4 patients.
Nine patients received a reduced-intensity conditioning regimen
with a fludrabine-melphalan-based regimen, and 4 myeloablative
conditioning (3 fludarabine-busulfan, 1 busulfan-cyclophosphamide).
Results: All patients engrafted, 75% achieved full donor chime-
rism, on day 30. Neutrophil and platelet engraftment occurred after
a median of 13 and 21.5 days. Twelve evaluable patients achieved re-
mission; 3 subsequently relapsed. JAK2V617F mutation became
negative after transplant in all tested patients and reappeared in 1 pa-
tient who later relapsed. Grade 2–4 aGVHD developed in 3 patients
(grade 3–4 in one) and cGVHD in 4/11 evaluable patients (extensive
in two). After a median follow-up of 17.2 months (range 7.2–128.6
mo), OS and EFS were 49% (SE 15%) and 44% (SE 14%), respec-
tively. Six patients died, related to disease relapse (2), pneumonia (2),
GVHD (1), and hepatic failure (1).
Conclusion: Patients with acute leukemia transformed from my-
elofibrosis with good performance status can achieve durable com-
plete remissions with ASCT.167
TOLERABILITY AND OUTCOMES OF A TARGETED INTRAVENOUS BUSUL-
FAN AND FLUDARABINE (T-BU/FLU) CONDITIONING REGIMEN FOR THE
TREATMENT DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA (AML)
Fernandez, H.F., Perkins, J., Field, T., Alsina, M., Ayala, E., Kharfan-
Dabaja,M., Ochoa, J.L., Perez, L., Raychaudhuri, J., Anasetti, C.Moffitt
Cancer Center, Tampa, FL
In an effort to reduce non-relapse mortality (NRM) and improve
survival in patients with AMLwe evaluated targeting busulfan to daily
AUCof 5300mmol/min/day. Since 2004we have treated 100 patients,
with de novo (66%) or secondary AML (34%), with a median age of 48
years (range 21–68)with a targeted IVbusulfan plus fludarabine (t-Bu/
Flu) reduced intensity regimen. 52 patients were in CR1, 23 in CR2
and 25 inadvanced AML. Of those in CR1, 50% had intermediate-
risk cytogenetics (IRC) and 50% had unfavorable-risk cytogenetics
(URC) at diagnosis. The patients were treated with t-BuFlu (Bu:
130–145 mg/m2/day on days 1 and 2 with pharmacokinetic targeting
for days 3 and 4; Flu 40mg/m2/day for 4 days). A median Bu AUC of
5265mmol/min/day was achieved. Patients received matched sibling
(38%), unrelated (40%), mismatched unrelated (21%) or mismatched
related (1%) HCT. GVHD prophylaxis consisted of tacrolimus plus
methotrexate or mycophenolate mofetil. Mismatched recipients re-
ceived rabbit ATG 7.5mg/kg as additional GVHD prophylaxis.
Results: NRM was 5% at 100 days and 17% at 1 year. Relapse
rates for patients in CR1 were 38.5 and 42.3 % (p 5 ns) for the
IRC and URC, respectively. With a median follow-up of 1 year,
EFS was 54% and OS was 57% at 1 year. There was a lower EFS
(63 vs. 30%, p 5 0.04) and a trend towards better OS (64 vs. 46%,
p5 0.07) for patient transplanted in CR1 compared to those beyond
first CR. There was no difference in the outcomes in EFS (p5 0.56)
or OS (p 5 0.98) between the IRC (n 5 56) and URC groups (n 5
40). Patients in first or second remission (n 5 74) had a better OS
(62 vs. 40%, p 5 0.04) than those not in remission (n 5 26) at the
time transplant. We noted a slight difference in outcomes based on
age below (n 5 66) or above (n 5 34) 55 years, but neither reached
statistical significance (EFS 58 vs. 44%, p 5 0.17; OS 60 vs. 49%,
Poster Session-I 63p 5 0.27). Cause of death was relapse 23%, aGVHD 2%, cGVHD
1%, infection 2%, MSOF/ ARDS 3% and other 2%. In conclusion:
the use of t-Bu/Flu in AML patients, with a daily AUC targeted at
5300610% is a tolerable regimen with lowNRM. It is also well tol-
erated regardless of age. Patients in a first CR, even those with URC,
have very good outcomes. Relapse is still an issue in these AML pa-
tients and post transplant therapy should be considered, particularly
for patients not in remission at the time of transplant. Currently we
are assessing the maximum tolerated AUC of Bu in an ongoing trial.168
SEQUENTIAL THERAPY WITH NONABLATIVE ALLOGENEIC STEM CELL
TRANSPLANTATION, POST TRANSPLANT IMATINIB AND DONOR LYM-
PHOCYTE INFUSION FOR CHRONIC MYELOID LEUKEMIA
Champlin, R.E., de Lima, M., Giralt, S., Kebriaei, P., Anderlini, P.,
Qazilbash, M., Hosing, C., Shpall, E., Fisher, T., Gabriela, R. MD An-
derson Cancer Center, Houston, TX
Allogeneic stem cell transplantation (ASCT) is a potentially cura-
tive therapy for patients(pts) with CML. Its use has declined because
of the favorable results of tyrosine kinase inhibitors (TKIs), and con-
cerns regarding toxicity andGVHD.The efficacy of ASCT is largely
due to the immune graft-vs.-leukemia effect. Nonmyeloablative con-
ditioning has reduced toxicity, and post transplant treatment with
imatinib and donor lymphocyte infusions can produce durable mo-
lecular complete remissions in pts with residual disease.We prospec-
tively studied use of a reduced intensity preparative regimen
involving fludarabine, busulfan and Thymoglobulin followed by
ASCT from an HLA identical or one antigen mismatched related
or unrelated donor. Pts who do not achieve molecular CR (mCR) af-
ter 3 mo received TKI treatment. Those without mCR after an ad-
ditional 3 mo received escalating doses of donor lymphocyte
infusion (DLI). 42 pts, median age 42 yrs (range 14–69) were en-
tered. All were previously treated with imatinib, but with detectable
disease. 20 had early disease (chronic phase or isolated clonal evolu-
tion) and 22 had advanced CML (prior accelerated or blast phase). 4
early and 9 advanced pts had a cytogenetic CR (CyCR) at the time of
transplant. The regimen was well tolerated without life-threatening
toxicity except for one pt with reversible transplant related microan-
gioapathy. Two pts had graft failure, one required a second trans-
plant and the other had autologous recovery with Ph-
hematopoiesis. Only one pt died within 100 days post transplant.
At 3 months, all of the chronic phase pts and 21 of the 18 advanced
pts achieved CyCR and 7 early and 5 advanced pts achieved a mCR.
22 pts received treatment with TKIs post transplant; mCR was
achieved in 7 of the 9 early pts and 2 of 13 advanced pts. 16 pts sub-
sequently received DLI; 2 of 2 pts with early disease achieved mCR
with one other pt too early to evaluate; 2 of 13 advanced pts have
a mCR. 31 pts are alive. This includes 18 of 20 (90%) transplanted
with early disease, (all in cCyR 13 in cMR) and 13 of the 22 (59%)
with advanced disease (7 in cCyR and 9 in cMR). This sequential
strategy of nonmyeloablative ASCT, post transplant TKIs, and
DLI is associated with a low treatment relatedmortality and deserves
further study to produce durable mCR in patients with a suboptimal
response to imatinib. Most favorable results were achieved in pts
without overt transformation.169
REDUCED INTENSITY CONDITIONING (RIC) REGIMEN FOLLOWEDBY AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN
ADULT PATIENTS (PTS) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Silva L., De Padua1, Saliba, R.1, Giralt, S.1, Hosing, C.1, Khouri, I.1,
Popat, U.1, Qazilbash, M.1, Shpall, E.1, Thomas, D.2, Kantarjian, H.2,
Champlin, R.1, Kebriaei, P.1 1The University of Texas MD Anderson
Cancer Center, Houston, TX; 2The University of Texas MD Anderson
Cancer Center, Houston, TX
Background:RIC regimens are less myelosuppressive, but still al-
low for successful engraftment with acceptable treatment-related
mortality (TRM) in frail pts who otherwise would not be suitable
candidates for HSCT. This is particularly relevant in ALL, since
pts often sustain toxicity from dose-intense regimens, or may bediagnosed in advanced age. The antitumor effect of this approach
is not well-established in ALL.
Methods: We evaluated 30 ALL pts (19 M/11 F) treated from
1996 to 2008 with fludarabine 120 mg/m2, melphalan 140 mg/m2
and unmanipulated stem cells. GVHD prophylaxis consisted of
tacrolimus and mini-methotrexate. Anti-thymocyte-globulin was
added to matched unrelated pts.
Results: Median age was 44 years (range 23–64). ECOG status at
time of HSCT was 0 (n 5 16), 1 (n 5 10) or 2 (n 5 4) with median
co-morbidity score of 3 (range 0–7) by Charlson Comorbidity Index.
24 pts had B-lineage and 6 had T-lineage disease. Cytogenetic data
were available for 26 pts; 19 had high-risk cytogenetics, including
9 with Ph1 disease. Disease stage at time of study entry was CR1
(n 5 5), $CR1 (n 5 12), or primary or refractory relapse (n 5 13),
with median 2 prior chemotherapy regimens (range 1–4); five pts
had a prior allogeneic HSCT. Donor type was matched related
(n 5 13) or matched unrelated (n 5 17) and stem cell source was
bone marrow (n5 14) or peripheral blood (n5 16). The median to-
tal nucleated cell dose and CD341 cell dose were 3.80  108 cells
(range 0.68 – 17.16) and 4.15 106 cells (range 1.78 – 12.03), respec-
tively. Median time to ANC 0.5  109/L was 13 days (range 10–24).
Median time to platelet count 20 109/L was 18 days (range 10–57).
Eight pts were alive at a median follow up of 12 months fromHSCT
(range 3–59). OS and DFS were 32% and 29%, respectively, at 1
year. Of note, only 1 among 5 pts in CR1 had disease progression,
compared to 8 among 13 with refractory disease at time of HSCT.
The cumulative incidence of acute GVHD, grades II-IV and III-
IV were 40% and 13%, respectively, and chronic GVHD was 22%
(7% for extensive). The cumulative incidence of TRM at 100 days
and 1 year were 17% and 33%, respectively. There were 22 deaths:
recurrence 14, infection 4, GVHD 4.
Conclusion: RIC HSCT can provide disease control in patients
with ALL, andmerits further evaluation. Alternative treatment strat-
egies need to be explored in pts with advanced disease. The observed
TRM rate is comparable to previously reported rates in in heavily
pre-treated leukemia patients.170
EPIGENETIC REGULATIONS INFLUENCE CML CELL SENSITIVITY TO
BUSULFAN: RELEVANCE TO PRETRANSPLANT CONDITIONING THERAPY
Valdez, B.C.1, Li, Y.1, Murray, D.2, Champlin, R.E.1, Andersson, B.S.1
1UTMDAnderson Cancer Center, Houston, TX; 2Cross Cancer Institute,
Edmonton, AB, Canada
Busulfan (Bu) is a DNA-alkylating drug which is commonly used
in myeloablative pretransplant conditioning therapy in patients with
CML. A major obstacle to successful treatment is inherent or
acquired cellular Bu-resistance. Knowing that DNA hypermethyla-
tion may contribute to drug resistance, we hypothesized that cellular
Bu-resistance can be reversed by altered epigenetic regulation. We
established a Bu-resistant CML cell line B5/Bu2506 which is 4-
fold more resistant to Bu than the parental B5 cells but 4-fold collat-
erally sensitive to 5-aza-2’-deoxycytidine (DAC). Real-time PCR
analysis of the expressions of known DNA methyltransferases
showed upregulation of DNMT3B in B5/Bu2506 cells relative to
the parental B5 cells without significant changes in DNMT1,
DNMT2, and DNMT3A. This result suggests that B5/Bu2506 cells
might be addicted to DNMT3B to epigenetically regulate expres-
sion of genes involved in Bu resistance; exposure to DAC might in-
hibit DNMT3B enzyme and sensitize cells to Bu. Indeed, exposure
to DAC synergistically increased Bu-mediated cytotoxicity in B5/
Bu2506 cells as evaluated by the MTT assay and median-effect anal-
ysis (combination index\ 0.5). The DAC-induced sensitivity to Bu
of B5/Bu2506 cells was associated with PARP1 cleavage, phosphor-
ylation of histone 2A and activation of caspases 3, 8 and 9 suggesting
induction of apoptotic response. Real-time PCR and immunostain-
ing analyses of the expressions of various viability-related genes,
which are known to be epigenetically regulated, showed significant
increase in the expression of CDKN2A (p16INK4A) and XAF1 (X-
linked inhibitor of apoptosis protein (XIAP)-associated factor 1)
genes in B5/Bu2506 cells exposed to DAC. Analyses of their
promoter regions by methylation-specific PCR showed a significant
decrease in their methylation status which correlates with the alter-
ation in their gene expression in the presence of DAC. The
